Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma

Mendel Goldfinger, Mina Xu, Joseph R. Bertino, Dennis L. Cooper

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

Lenalidomide has modest single-agent activity comparable with other newer drugs in recurrent diffuse large B cell lymphoma with response rates between 19% and 28%. Retrospective series and 1 prospective study suggest that clinically significant responses were predominantly limited to patients with activated B cell (ABC) lymphoma, a finding in agreement with lenalidomide's potent inhibition of nuclear factor κB, the key driver of ABC lymphomas. Recently completed trials will determine whether the additional use of lenalidomide with R/CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) enhances survival compared with R/CHOP alone and whether this activity is limited to ABC lymphomas. Lenalidomide also appears to have activity in the maintenance setting regardless of cell of origin and might play an important role in patients with recurrent disease who are not transplantation candidates. Similarly, because of the ability of lenalidomide to cross the blood–brain barrier, it needs to be further explored in patients with high risk for central nervous system spread. The results of lenalidomide combination studies with chemotherapy and with checkpoint inhibitors are eagerly awaited.

Original languageEnglish (US)
Pages (from-to)e307-e311
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number6
DOIs
StatePublished - Jun 2019
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
lenalidomide
Central Nervous System
Transplantation
Maintenance
Prospective Studies
Drug Therapy
Survival
Pharmaceutical Preparations

Keywords

  • Activated B-cell
  • Cell of origin
  • Germinal center
  • PDL-1
  • Revlimid

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. / Goldfinger, Mendel; Xu, Mina; Bertino, Joseph R.; Cooper, Dennis L.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 19, No. 6, 06.2019, p. e307-e311.

Research output: Contribution to journalComment/debate

Goldfinger, Mendel ; Xu, Mina ; Bertino, Joseph R. ; Cooper, Dennis L. / Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma. In: Clinical Lymphoma, Myeloma and Leukemia. 2019 ; Vol. 19, No. 6. pp. e307-e311.
@article{9ba0991eb89e4dd0b19be4d0f15837da,
title = "Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma",
abstract = "Lenalidomide has modest single-agent activity comparable with other newer drugs in recurrent diffuse large B cell lymphoma with response rates between 19{\%} and 28{\%}. Retrospective series and 1 prospective study suggest that clinically significant responses were predominantly limited to patients with activated B cell (ABC) lymphoma, a finding in agreement with lenalidomide's potent inhibition of nuclear factor κB, the key driver of ABC lymphomas. Recently completed trials will determine whether the additional use of lenalidomide with R/CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) enhances survival compared with R/CHOP alone and whether this activity is limited to ABC lymphomas. Lenalidomide also appears to have activity in the maintenance setting regardless of cell of origin and might play an important role in patients with recurrent disease who are not transplantation candidates. Similarly, because of the ability of lenalidomide to cross the blood–brain barrier, it needs to be further explored in patients with high risk for central nervous system spread. The results of lenalidomide combination studies with chemotherapy and with checkpoint inhibitors are eagerly awaited.",
keywords = "Activated B-cell, Cell of origin, Germinal center, PDL-1, Revlimid",
author = "Mendel Goldfinger and Mina Xu and Bertino, {Joseph R.} and Cooper, {Dennis L.}",
year = "2019",
month = "6",
doi = "10.1016/j.clml.2019.02.012",
language = "English (US)",
volume = "19",
pages = "e307--e311",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Checking in on Lenalidomide in Diffuse Large B Cell Lymphoma

AU - Goldfinger, Mendel

AU - Xu, Mina

AU - Bertino, Joseph R.

AU - Cooper, Dennis L.

PY - 2019/6

Y1 - 2019/6

N2 - Lenalidomide has modest single-agent activity comparable with other newer drugs in recurrent diffuse large B cell lymphoma with response rates between 19% and 28%. Retrospective series and 1 prospective study suggest that clinically significant responses were predominantly limited to patients with activated B cell (ABC) lymphoma, a finding in agreement with lenalidomide's potent inhibition of nuclear factor κB, the key driver of ABC lymphomas. Recently completed trials will determine whether the additional use of lenalidomide with R/CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) enhances survival compared with R/CHOP alone and whether this activity is limited to ABC lymphomas. Lenalidomide also appears to have activity in the maintenance setting regardless of cell of origin and might play an important role in patients with recurrent disease who are not transplantation candidates. Similarly, because of the ability of lenalidomide to cross the blood–brain barrier, it needs to be further explored in patients with high risk for central nervous system spread. The results of lenalidomide combination studies with chemotherapy and with checkpoint inhibitors are eagerly awaited.

AB - Lenalidomide has modest single-agent activity comparable with other newer drugs in recurrent diffuse large B cell lymphoma with response rates between 19% and 28%. Retrospective series and 1 prospective study suggest that clinically significant responses were predominantly limited to patients with activated B cell (ABC) lymphoma, a finding in agreement with lenalidomide's potent inhibition of nuclear factor κB, the key driver of ABC lymphomas. Recently completed trials will determine whether the additional use of lenalidomide with R/CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) enhances survival compared with R/CHOP alone and whether this activity is limited to ABC lymphomas. Lenalidomide also appears to have activity in the maintenance setting regardless of cell of origin and might play an important role in patients with recurrent disease who are not transplantation candidates. Similarly, because of the ability of lenalidomide to cross the blood–brain barrier, it needs to be further explored in patients with high risk for central nervous system spread. The results of lenalidomide combination studies with chemotherapy and with checkpoint inhibitors are eagerly awaited.

KW - Activated B-cell

KW - Cell of origin

KW - Germinal center

KW - PDL-1

KW - Revlimid

UR - http://www.scopus.com/inward/record.url?scp=85063276258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063276258&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.02.012

DO - 10.1016/j.clml.2019.02.012

M3 - Comment/debate

C2 - 30926391

AN - SCOPUS:85063276258

VL - 19

SP - e307-e311

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -